TriSalus Life Sciences (NASDAQ:TLSI) Rating Reiterated by Canaccord Genuity Group

TriSalus Life Sciences (NASDAQ:TLSI)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity Group in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $12.00 price target on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 117.39% from the company’s previous close.

Several other equities research analysts have also recently issued reports on TLSI. Canaccord Genuity Group assumed coverage on shares of TriSalus Life Sciences in a research report on Thursday, May 30th. They issued a “buy” rating and a $12.00 price objective for the company. Jonestrading assumed coverage on shares of TriSalus Life Sciences in a research report on Friday, May 10th. They issued a “buy” rating and a $16.00 price objective for the company.

TriSalus Life Sciences Stock Down 4.2 %

TLSI stock opened at $5.52 on Thursday. TriSalus Life Sciences has a 12 month low of $3.32 and a 12 month high of $16.24. The company has a 50-day moving average price of $8.02 and a 200 day moving average price of $8.74.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.54) earnings per share (EPS) for the quarter. The business had revenue of $6.46 million for the quarter.

Institutional Investors Weigh In On TriSalus Life Sciences

An institutional investor recently bought a new position in TriSalus Life Sciences stock. HC Advisors LLC acquired a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 101,736 shares of the company’s stock, valued at approximately $860,000. HC Advisors LLC owned approximately 0.39% of TriSalus Life Sciences as of its most recent SEC filing. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.